[Kidney transplantation].
From March 1986 to August 1994, 110 living-related renal transplants were performed under the cyclosporine combination immunosuppression. Age of the recipients ranged from 4 to 48 years old (mean 29.3), and 81 patients were male and 29 were female. The mean duration on dialysis before the transplants were 39.7 months (0 to 210), and the methods of dialysis were divided with hemodialysis in 94 patients, CAPD in 15 and no dialysis in 1. The donors consisted of 96 parents (87.3%), 66 mothers and 30 fathers, and 14 siblings (12.7%). Age of the donors ranged from 28 to 73 years old (mean 48.7). The number of patients with acute rejection episodes were 48 patients with once, 18 with twice, 10 with 3 times and 34 (30.9%) with no rejection. Patient survival rate was 99.0% after 1 year posttransplantation, 97.9% after 3 years and 95.7% after 5 years. Graft survival rate was 91.5%, 85.1% and 77.8%, respectively. Twenty grafts were lost with the most common causes of graft loss being chronic rejection (55%), acute rejection (20%) and accelerated acute rejection (15%). In cadaveric renal transplants, because of very small number of informations for cadaver donor, only 13 cadaveric renal transplants were performed in Hokkaido, from 1984 to August 1994. There was no case over 5 years follow up postoperatively, so patient survival rate was 100% and 90% after 1 year and 3 years posttransplantation, and graft survival rate was 84.6% and 74.0%, respectively. Two kidneys of 13 cadaveric renal transplants were never functioning grafts. We have to make more efforts for propagation of the donation system.
Kanagawa
K
K
Department of Urology, Asahikawa City Hospital, Japan.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014019:Tissue Donors
D007166:Immunosuppressive Agents